

Product Data Sheet

Product Name: Enzomenib enantiomer

Cat. No.: GC80857

Chemical Properties

Cas. No.

Formula $C_{33}H_{43}FN_6O_3$

M.Wt 590.73


Solubility

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Enzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib. Enzomenib (DSP-5336) is an orally active Menin inhibitor ($IC_{50} = 1.4$ nM, $K_d = 6.0$ nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations [1] [2] [3].

References:

- [1]. Chen T, et al. Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives. *Oncol Res.* 2026;34(3):4. Published 2026 Feb 24.
- [2]. Daver N, et al. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation[J]. *Blood*, 2021, 138: 4431.
- [3]. Eguchi K, et al. Preclinical evaluation of a novel orally bioavailable menin-MLL interaction inhibitor, DSP-5336, for the treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation[J]. *Blood*, 2021, 138: 3339.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA